Later‐Stage Diagnosis and Poorer Survival in Pancreatic Cancer Patients With Vague Symptoms: A Population‐Based Study
Spätere Diagnose und schlechteres Überleben bei Patient:innen mit Pankreaskrebs und vagen Symptomen: populationsbasierte Studie
United European Gastroenterology Journal · 2026-05 · 14 (4)
DOI: 10.1002/ueg2.70231 ↗Auf einen Blick
Bei 512 Pankreaskrebs-Patient:innen waren vage Symptome häufiger als Alarmsymptome. Vage Symptome waren mit Stadium IV und geringerem 1-Jahres-Überleben verbunden.
Fragestellung
Zusammenhang von Alarmsymptomen vs. vagen Symptomen mit Diagnoseweg, Stadium, Therapie und Überleben bei Pankreaskrebs
Methode
Populationsbasierte Analyse des Northern Ireland Cancer Registry PC Audit 2019–2020; 512 Fälle; χ2-Tests, Kaplan-Meier/Log-Rank und Cox-Modelle mit Adjustierung.
Ergebnisse
Vage Symptome: 60,4 % vs. 39,6 % Alarmsymptome. Stadium IV: 62,1 % vs. 39,9 %; tumorreduktive Therapie: 34,0 % vs. 50,2 %; 1-Jahres-Überleben: 24,9 % vs. 33,7 %. HR 1,48 (1,14–1,91).
Schlussfolgerung der Autor:innen
Patient:innen mit vagen Symptomen wurden häufiger über die Hausarztpraxis vorgestellt, hatten häufiger spätere Stadien und ein schlechteres Überleben. Vage Symptome blieben unabhängig mit schlechterem Überleben assoziiert.
Kernaussagen
- Vage Symptome waren häufiger als Alarmsymptome
- Stadium IV und weniger tumorreduktive Therapie bei vagen Symptomen
- Unabhängig schlechteres Überleben: HR 1,48 (1,14–1,91)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 15.05.2026. Verfasst von Vinay Murali Prasad und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, Northern Ireland, UK. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Delayed Diagnosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northern Ireland Pancreatic Cancer, Public Health Agency.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Most pancreatic cancer (PC) patients present symptomatically to cancer services, are diagnosed at late stage, and have poor survival. Patients with alarm symptoms (AS), such as jaundice or altered stool/urine colour, may be more readily recognised within current referral pathways than those with vague symptoms (VS).
Objective
To examine the associations of presenting symptom category (alarm vs. vague) with route to diagnosis, stage at diagnosis, treatment, and survival in PC patients.
Methods
Of 540 primary PC cases identified in the population‐based Northern Ireland Cancer Registry PC Audit (2019–2020), 28 were excluded because referral pathway information was insufficient to classify route to diagnosis, leaving 512 patients for analysis. Patients were categorised by presenting symptoms as AS or VS. χ 2 tests assessed group differences; Kaplan‐Meier and Log‐Rank tests compared 1‐year survival. Cox proportional hazards models compared mortality risk, adjusting for sex, age, socioeconomic status, referral route, tumour location, and stage at diagnosis. All statistical tests were two‐sided, and p < 0.05 was considered statistically significant.
Results
More patients presented with VS (60.4%) than AS (39.6%). Emergency admission was more common in AS than in VS patients (66.0% vs. 33.7%, p < 0.001). VS patients more often had stage IV disease (62.1% vs. 39.9%, p < 0.001) and were less likely to receive tumour‐reductive treatment (34.0% vs. 50.2%, p < 0.001). One‐year survival was poorer in VS than in AS patients (24.9% vs. 33.7%, p = 0.001). VS was associated with a 48% increased mortality risk [HR = 1.48 (1.14–1.91)] after full adjustment.
Conclusion
PC patients with VS were more often presented via GP; they had later‐stage disease and poorer survival. VS remained independently associated with poorer survival. Greater awareness of PC symptoms, especially VS, together with effective diagnostic pathways for non‐specific symptoms, may help support more timely investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, Northern Ireland, UK.
- Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, Northern Ireland, UK.
- Northern Ireland Cancer Registry, Centre for Public Health, Queen's University, Belfast, Northern Ireland, UK.
- Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
ORCID-Profile: Vinay Murali Prasad, Damien Bennett
Förderung
- Northern Ireland Pancreatic Cancer
- Public Health Agency
Zitieren
APA
Prasad, V. M., Coleman, H. G., Hawkins, S. T., Mitchell, H., McCain, S., Johnston, D., & Bennett, D. (2026). Later‐Stage Diagnosis and Poorer Survival in Pancreatic Cancer Patients With Vague Symptoms: A Population‐Based Study. United European Gastroenterology Journal, 14(4). https://doi.org/10.1002/ueg2.70231
Vancouver
Prasad VM, Coleman HG, Hawkins ST, Mitchell H, McCain S, Johnston D, et al. Later‐Stage Diagnosis and Poorer Survival in Pancreatic Cancer Patients With Vague Symptoms: A Population‐Based Study. United European Gastroenterology Journal. 2026;14(4). doi:10.1002/ueg2.70231
BibTeX
@article{Prasad2026,
author = {Prasad, Vinay Murali and Coleman, Helen G and Hawkins, Sinead T and Mitchell, Helen and McCain, Stephen and Johnston, Dorothy and Bennett, Damien},
title = {Later‐Stage Diagnosis and Poorer Survival in Pancreatic Cancer Patients With Vague Symptoms: A Population‐Based Study},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/ueg2.70231}
}
EUVIMED